The Paris Life Sciences team advised nextProtein, an AgTech specializing in sustainable insect-based protein production, on its €18 million Series B financing round to accelerate its insect protein production.
The round was jointly led by Swen Capital through its Blue Ocean fund and British International Investment, the UK’s development finance institution and impact investor, alongside existing investors Mirova and RAISE Impact, as well as a consortium of banks providing a €4 million senior loan.
This new investment will enable nextProtein to significantly scale its operations, particularly through the opening of a second production facility designed to produce 12,000 tonnes of insect-based ingredients annually (including 2,500 tonnes of protein flour), as part of its strategy to reach profitability.
Founded in 2015, nextProtein produces insect-based protein and oil for the animal food industry, contributing to sustainable agriculture and resource management. Its proprietary technology raises black soldier fly larvae on low-grade agricultural by-products, transforming them into cost-efficient, high-quality ingredients for aquaculture, livestock, and pets. By utilizing underexploited raw materials, nextProtein strengthens its competitiveness while generating significant environmental benefits, such as reduced land and water consumption and lower carbon emissions.
The Goodwin team included Anne-Charlotte Rivière (partner), Julie Messerig and Valentine Nuaud and Grégoire Mongis (associates) on corporate matters, as well as Adrien Paturaud (partner), Alexander Hahn, Charlotte Mouradian, and Sacha Roustier (associates) on financing aspects.